The US Food and Drug Administration on Monday authorized emergency use of Eli Lilly and Co’s experimental Covid-19 antibody treatment for non-hospitalized patients older than 65 or who have certain chronic medical conditions.

The FDA said its emergency use authorization (EUA) was based on clinical trials showing that the treatment, bamlanivimab, reduced the need for hospitalization or emergency room visits in Covid-19 patients at high risk of disease progression.

It can now be used for treating mild-to-moderate Covid-19 in adults and pediatric patients over the age of 12, the FDA said.

The antibody is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy due to Covid-19. The FDA said the drug, which U.S. President Donald Trump has praised, had not been shown to benefit such patients and could worsen their clinical status.

A US government-sponsored study of the treatment in hospitalized Covid-19 patients was recently abandoned because the treatment.